Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that fractional Er:YAG laser combined with platelet-rich plasma resulted in greater skin repigmentation in patients with localized stable vitiligo compared to microneedling with platelet-rich plasma, with fewer side effects reported in the laser group.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study found that combining topical minoxidil with phototherapy significantly improved pigmentation and reduced vitiligo severity compared to placebo, as measured by VASI scores over 12 weeks, though the sample size was small and follow-up short.

This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway.

This review examines the use of computer vision techniques, specifically deep learning architectures and image processing algorithms, for detecting and assessing skin conditions like vitiligo and dermatitis, and highlights the need for disease-specific datasets to improve automated diagnostic tools in dermatology.

In this study, individualized homoeopathic treatment with Silicea showed a marked reduction in depigmentation for a case of vitiligo, with a likely causal link suggested by evaluation criteria.

This study found no significant difference in serum prolactin levels between vitiligo patients and healthy controls, nor any significant association between prolactin gene polymorphism and vitiligo severity, except for a significant relation with BMI.

This study concluded that the topical gel VB1953 reduced inflammatory and non-inflammatory acne lesions and resistant bacteria in patients with clindamycin-resistant acne, showing promise as an effective treatment.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This study found that patients with vitiligo and alopecia areata had significantly higher serum granulysin levels compared to healthy controls, indicating a potential pathogenic role and suggesting that elevated levels may serve as a biomarker for monitoring disease activity, particularly in active vitiligo cases.

This review discusses the efficacy and safety of topical JAK inhibitors for inflammatory skin conditions, reporting modest benefits in psoriasis and atopic dermatitis but mixed results for vitiligo and inconclusive data for alopecia areata.

In this study, alopecia areata and vitiligo patients had significantly lower serum BDNF and vitamin D levels, which were inversely associated with depression and quality of life, suggesting a potential combined role in the development of depression.

This study examined the safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis, finding that it was well tolerated and significantly improved symptoms over 52 weeks, with its safety profile similar to that in adults.

This clinical trial found that topical application of Sandalore® 1% significantly reduced hair shedding and increased hair volume in women with telogen effluvium compared to placebo.

This study observed that people with autoimmune blistering skin disorders report higher food intolerance rates, particularly avoiding alcohol, citrus, and spicy foods, and suggests potential dietary influences on symptom management.

This case report describes a 77-year-old woman with female pattern hair loss and elevated testosterone levels, who showed no improvement with minoxidil and lacked adrenal tumors on imaging.

This study suggests that combining baricitinib with narrowband UV-B therapy is an effective and well-tolerated approach for treating active nonsegmental vitiligo.

This study identified distinct plasma miRNA profiles in alopecia areata that may aid in diagnosis and therapy, but further validation is needed to confirm these exploratory findings.

This review covers the use of JAK inhibitors in treating various dermatological conditions, emphasizing their potential while noting ongoing safety concerns with oral treatments; no new clinical results are provided.

This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

In this review, researchers examined the link between microorganisms and vitiligo, highlighting how microbes might impact the disease's development and suggesting avenues for better treatment strategies based on these interactions.

This study suggests that HDAC inhibitors, such as Vorinostat and Entinostat, could be effective in promoting hair regrowth in a mouse model of alopecia areata.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

In this study, different donor and recipient site preparation techniques for melanocyte-keratinocyte suspension were associated with similar repigmentation outcomes in stable vitiligo, but efficacy varied by body site.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

This review discusses various dermatological scoring systems used to objectively assess disease severity and guide treatment decisions, reporting no new clinical results.

This source discusses the potential of topical JAK inhibitors, like tofacitinib, as effective treatments for autoimmune skin diseases, emphasizing their superior safety profile and minimal adverse effects compared to conventional systemic therapies.